Issaragrisil S, Piankijagum A, Tang-naitrisorana Y
Am J Hematol. 1987 May;25(1):77-83. doi: 10.1002/ajh.2830250108.
We evaluated the efficacy of alternate day, high dose prednisolone for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Nineteen patients were included. Thirteen were men and six were women, aged between 13-56 years. Eleven patients improved, eight with good response and three with fair response. Eight patients were non-responders. Responders had gradual improvement in the hemoglobin level, but none achieved a normal hemoglobin level. Age at diagnosis, sex, initial hemoglobin, white count, and percentage of a positive Ham's test had no apparent bearing on treatment outcome. A prolonged interval from diagnosis to prednisolone treatment decreased the chance of a favorable hematologic response to therapy. Age at the treatment in non-responders was higher than responders. Responders had higher numbers of colonies derived from BFU-E and CFU-GM both in the blood and bone marrow than non-responders although the differences did not achieve statistical significance. These data indicate that alternate day, high dose prednisolone therapy is effective in some patients with PNH.
我们评估了隔日大剂量泼尼松龙治疗阵发性夜间血红蛋白尿(PNH)的疗效。共纳入19例患者,其中男性13例,女性6例,年龄在13至56岁之间。11例患者病情改善,8例反应良好,3例反应尚可。8例患者无反应。有反应者血红蛋白水平逐渐升高,但均未达到正常血红蛋白水平。诊断时的年龄、性别、初始血红蛋白、白细胞计数及酸化血清溶血试验阳性百分比与治疗结果无明显关联。从诊断到开始泼尼松龙治疗的间隔时间延长会降低血液学治疗反应良好的几率。无反应者的治疗年龄高于有反应者。尽管差异无统计学意义,但有反应者血液和骨髓中源自爆式红系集落形成单位(BFU-E)和粒-巨噬细胞集落形成单位(CFU-GM)的集落数量均多于无反应者。这些数据表明,隔日大剂量泼尼松龙治疗对部分PNH患者有效。